Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 22 of 114, showing 5 Applications out of 567 total, starting on record 106, ending on 110

# Protocol No Study Title Investigator(s) & Site(s)

106.

ECCT/25/05/05   Hibiscus 2 - Site 252
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county)
 
View

107.

ECCT/25/05/03   Hibiscus 2 - Site 253
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Site 253 - International Cancer Institute (Uasin Gishu county)
 
View

108.

ECCT/25/05/06   Hibiscus 2 - Site 254
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county)
 
View

109.

ECCT/25/05/02   Hibiscus 2 - Site 251
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. Site 251 - Ahero Clinical Trails Unit, CREATES Strathmore University (Kisumu county)
 
View

110.

ECCT/24/08/02   S4V02
    Safety and immunogenicity of a second generation Shigella bioconjugate vaccine: a phase II randomized, controlled, and blinded study in 9-month-old infants   
Principal Investigator(s)
1. Richard Omore
Site(s) in Kenya
Siaya County Referral Hospital
 
View